Drug Profile
ALXN 5500
Alternative Names: ALXN5500Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease
- Class Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 28 Jul 2018 No recent reports of development identified for phase-I development in Immunological-disorders in USA (Parenteral)
- 01 Jul 2014 Phase-I clinical trials in Immunological disorders in USA (unspecified route)